AstraZeneca has invested heavily in our Augmented Drug Design-Make-Test and Analyse platforms as we seek to deliver better, differentiated candidate drugs into trials, faster, for greater patient benefit. We have made great strides in creating an ecosystem enabling operational and experimental data capture, and in developing AI/ML analytics, AI, and ML services for both traditional small molecules and complex modalities that will pave the way for this transformation. The next stage of this journey involves building a unified scientific data and AI platform with state-of-the-art algorithms and technology...